CPRX - Catalyst Pharmaceuticals Non-GAAP EPS of $0.28 beats by $0.11 revenue of $53.11M beats by $4.03M re-affirms FY22 guidance
- Catalyst Pharmaceuticals press release ( NASDAQ: CPRX ): Q2 Non-GAAP EPS of $0.28 beats by $0.11 .
- Revenue of $53.11M (+46.0% Y/Y) beats by $4.03M .
- The Company continues to forecast that its full year 2022 total revenues will be in the range of between $195 million and $205 million, representing a 38% - 45% increase in total revenues compared to 2021.
- Cash operating expenses for the full year 2022 expected to be in the range of $65 million to $70 million.
- Adjusted EBITDA expected to be in the range of $100-105 million.
For further details see:
Catalyst Pharmaceuticals Non-GAAP EPS of $0.28 beats by $0.11, revenue of $53.11M beats by $4.03M, re-affirms FY22 guidance